Higher Dosing Shows Positive Effects on
Cognitive Function
NEW
YORK, June 6, 2023 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused
biopharmaceutical company, today announced that HT-ALZ a
therapeutic in development for the treatment of Alzheimer's disease
achieved positive preclinical results that outpaced its pervious
study. In particular, the higher dose appears to be most
beneficial in a spatial memory test performed at Washington University in St Louis.
Hoth has now completed the behavior results for Locomotor
Activity/Exploratory Behavior, Elevated Plus Maze, Spatial
Navigation Water Maze, Prepulse Inhibition of Startle, and
Conditioned Fear and looks forward to sharing further data as it
becomes available.
"This recently completed phase of our studies in conjunction
with Washington University is a
positive step forward and we now will begin processing the brains
of the animal subjects for total plaque load and
soluble/insoluble beta amyloid levels," said Robb Knie, CEO of Hoth Therapeutics.
AD is a neurodegenerative disease that is characterized by
aggregates of amyloid β (Aβ) plaques and neurofibrillary tangles of
Tau protein in the brain, which contribute to the clinical symptoms
of the disease such as dementia. Previously Hoth reported study
results focused on investigating the effect of orally administered
HT-ALZ to reduce the concentration of Aβ in the brain interstitial
fluid, using an established Alzheimer's Disease mouse model (aged
APP/PS1+/- mice). The initial data from those studies showed a
significant decrease in Aβ in both male and female APP/PS1+/- mice
after acute treatment with HT-ALZ, compared to placebo-treated
animals and baseline Aβ levels.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a
clinical-stage biopharmaceutical company dedicated to develop
innovative, impactful, and ground-breaking treatments with a goal
to improve patient quality of life. We are a catalyst in
early-stage pharmaceutical research and development, elevating
drugs from the bench to pre-clinical and clinical testing.
Utilizing a patient-centric approach, we collaborate and partner
with a team of scientists, clinicians, and key opinion leaders to
seek out and investigate therapeutics that hold immense potential
to create breakthroughs and diversify treatment options. To learn
more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes
forward-looking statements based upon Hoth's current expectations
which may constitute forward-looking statements for the purposes of
the safe harbor provisions under the Private Securities Litigation
Reform Act of 1995 and other federal securities laws, and are
subject to substantial risks, uncertainties and assumptions. These
statements concern Hoth's business strategies; the timing of
regulatory submissions; the ability to obtain and maintain
regulatory approval of existing product candidates and any other
product candidates we may develop, and the labeling under any
approval we may obtain; the timing and costs of clinical trials,
the timing and costs of other expenses; market acceptance of our
products; the ultimate impact of the current Coronavirus pandemic,
or any other health epidemic, on our business, our clinical trials,
our research programs, healthcare systems or the global economy as
a whole; our intellectual property; our reliance on third party
organizations; our competitive position; our industry environment;
our anticipated financial and operating results, including
anticipated sources of revenues; our assumptions regarding the size
of the available market, benefits of our products, product pricing,
timing of product launches; management's expectation with respect
to future acquisitions; statements regarding our goals, intentions,
plans and expectations, including the introduction of new products
and markets; and our cash needs and financing plans. There are a
number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
You should not place reliance on these forward-looking statements,
which include words such as "could," "believe," "anticipate,"
"intend," "estimate," "expect," "may," "continue," "predict,"
"potential," "project" or similar terms, variations of such terms
or the negative of those terms. Although the Company believes that
the expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section entitled "Risk Factors" in
Hoth's most recent Annual Report on Form 10-K and Hoth's other
filings made with the U. S. Securities and Exchange Commission. All
such statements speak only as of the date made. Consequently,
forward-looking statements should be regarded solely as Hoth's
current plans, estimates, and beliefs. Investors should not place
undue reliance on forward-looking statements. Hoth cannot guarantee
future results, events, levels of activity, performance or
achievements. Hoth does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-preclinical-results-of-ht-alz-treatment-for-alzheimers-disease-301843575.html
SOURCE Hoth Therapeutics, Inc.